212 related articles for article (PubMed ID: 11816268)
1. Rosuvastatin for the treatment of patients with hypercholesterolemia.
Chong PH; Yim BT
Ann Pharmacother; 2002 Jan; 36(1):93-101. PubMed ID: 11816268
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Yee HS; Fong NT
Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
[TBL] [Abstract][Full Text] [Related]
3. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.
Olsson AG; McTaggart F; Raza A
Cardiovasc Drug Rev; 2002; 20(4):303-28. PubMed ID: 12481202
[TBL] [Abstract][Full Text] [Related]
4. Rosuvastatin: a high-potency HMG-CoA reductase inhibitor.
Lopez LM
J Am Pharm Assoc (2003); 2005; 45(4):503-13. PubMed ID: 16128507
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic interaction between ezetimibe and rosuvastatin.
Kosoglou T; Statkevich P; Yang B; Suresh R; Zhu Y; Boutros T; Maxwell SE; Tiessen R; Cutler DL
Curr Med Res Opin; 2004 Aug; 20(8):1185-95. PubMed ID: 15324521
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin in the management of hyperlipidemia.
Cheng JW
Clin Ther; 2004 Sep; 26(9):1368-87. PubMed ID: 15531000
[TBL] [Abstract][Full Text] [Related]
7. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).
Bays HE; Davidson MH; Massaad R; Flaim D; Lowe RS; Tershakovec AM; Jones-Burton C
Am J Cardiol; 2011 Aug; 108(4):523-30. PubMed ID: 21596364
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial.
Ballantyne CM; Miller E; Chitra R
Clin Ther; 2004 Nov; 26(11):1855-64. PubMed ID: 15639697
[TBL] [Abstract][Full Text] [Related]
10. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
12. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M
Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
[TBL] [Abstract][Full Text] [Related]
14. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
15. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.
Olsson AG; Istad H; Luurila O; Ose L; Stender S; Tuomilehto J; Wiklund O; Southworth H; Pears J; Wilpshaar JW;
Am Heart J; 2002 Dec; 144(6):1044-51. PubMed ID: 12486429
[TBL] [Abstract][Full Text] [Related]
16. A new statin: a new standard.
Olsson AG
Clin Cardiol; 2001 Aug; 24(8 Suppl):III18-23. PubMed ID: 11501599
[TBL] [Abstract][Full Text] [Related]
17. Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
Cheng-Lai A
Heart Dis; 2003; 5(1):72-8. PubMed ID: 12549990
[TBL] [Abstract][Full Text] [Related]
18. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
19. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials.
Catapano A; Brady WE; King TR; Palmisano J
Curr Med Res Opin; 2005 Jul; 21(7):1123-30. PubMed ID: 16004682
[TBL] [Abstract][Full Text] [Related]
20. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
Meek C; Wierzbicki AS; Jewkes C; Twomey PJ; Crook MA; Jones A; Viljoen A
Curr Med Res Opin; 2012 Mar; 28(3):371-8. PubMed ID: 22256801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
